

Investor Presentation

(Teaser Version)

September 2025



**First-to-market nebulized
GLP/GIP Offering**


FinalFixRx Product Line

Breathe Better Health

Women'sHealth

Woman's World
Life&Style

Men'sHealth



© 2025 SIMPLEFIX | CONFIDENTIAL | NOT FOR DISTRIBUTION

Disclaimer: Content in this presentation is subject to change with additional details

Product Offering

"Developed by the team behind leading injectable GLP/GIP solutions — and deeply committed to understanding and supporting patients throughout their health journeys — SimpleFix is proud to introduce FinalFixRx: the first-to-market, needle-free GLP/GIP nebulizer product line designed to transform patient care."

– Founder/CEO Chanelle Bevilacqua

- **Safe** – FDA-cleared, registered, and approved
- **Effective** – Clinically supported for reliable outcomes
- **Accessible** – Designed for comfort, convenience, and adherence



The Problem & Solution

Key Pain Points:

Injection Aversion:

Over **40% of patients** prescribed injectables report **non-compliance due to needle anxiety, pain, or injection fatigue**.

[Source: [Clinical Therapeutics Volume 38, Issue 7, July 2016](#)]

Pediatrics Growth & On-the-Go Users with Adherence Challenges:

While GLP-1 treatments are expanding into pediatric use and more patients are managing therapy while on the go, current delivery methods — typically weekly, refrigerated injectables — remain cumbersome, inconvenient, and require careful handling, key factors leading to low adherence.

[Source: [Pharmacists and Pediatric Medication Adherence: Bridging the Gap – Feb 2017](#)]

[Source: [Evolving Trends in GLP/GIP Receptor Agonist Prescriptions for Pediatric Type 2 Diabetes – June 2025](#)]

Missed Market: Those Looking to Quit Vaping

Nearly **16 million U.S. adults vape**, of which **over 60% want to quit**, and **nearly 14% do so strictly to loss weight**, yet few supportive, health-enhancing alternatives exist.

[Source: [Majority of e-cigarette users want to quit, study finds – April 2021](#)]

[Source: [Vaping to lose weight – March 2017](#)]

Current GLP/GIP Delivery Models Are Rigid:

Market is dominated by **injectable and oral-only GLP/GIP drugs** with **slow absorption**, side effects, and higher discontinuation rates (as high as 50% among obesity only patients).

[Source: [GLP/GIP Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes \(T2D\) – May 2024](#)]

The Stakes Are High:

GLP/GIP medications have been shown to **reduce major cardiovascular events by 20%**, support sustained **10–15% body weight loss** and dramatically **improve glycemic control** in patients with Type 2 diabetes and obesity.

The Market & Growth

Widespread Consumer Demand Fuels GLP/GIP Market Growth

60% of US consumers are currently trying to lose weight, and 50% are considering GLP/GIP

[Source: McKinsey & Company. [The trends defining the \\$1.8 trillion global wellness market in 2024](#)]

GLP/GIP Therapies Are Reshaping Drug Spending & Adoption Trends

GLP/GIP utilization is now outpacing traditional specialty drug growth — with weight loss prescriptions expected to rise over 70% in 2025. Global adoption is projected to grow at 17.5% CAGR, with North America accounting for 76% of the market share.

[Source: [Evernorth Health Services](#) (parent company of Cigna). [Navigating GLP/GIP cost, demand and sustainability](#)]

[Source: [Towards Healthcare](#). [GLP/GIP Receptor Agonist Market Size & Worldwide Demand 2023-34](#)]

U.S. Population with Obesity and Type 2 Diabetes

Condition	Estimated # of Americans	% of U.S. Population
Obesity (BMI ≥ 30)	~110 million	~42%
Severe Obesity (BMI ≥ 40)	~36 million	~12%
Type 2 Diabetes (Diagnosed)	~34 million	~13%
Prediabetes	~96 million	~38%

19.1 million patients were prescribed GLP-1 medication in 2024

Core target market for GLP/GIP Adopters (~36 million distinct Americans)

Only 11.2% of eligible patients with obesity or Type 2 diabetes are taking GLP-1 medication

[Source: [NIH](#). [Obesity and Type 2 Diabetes in Children: Epidemiology and Treatment](#)]

[Source: [CDC](#). [Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023](#)]

[Source: [Healthverity](#). [The GLP-1 trend: What the real-world data reveals, June 2025](#)]

Addressable Market

US Addressable to Serviceable Obtainable Market (SOM)

Market Category	Adults (18+)	Pediatrics (12–17)	Total
TAM	30M	~6M	~36M
SAM	~6M	~1M	~7M
SOM (3 yrs)	~170K	~10–20K	~180K

Average Nationwide Spend per Patient on GLP/GIP:

Pricing: \$1,540 per 3-month prescription = \$6,160 annually

[Source: [Medpage Today](#). [GLP/GIP Spending Hit \\$5.8 Billion in 2022 for U.S. Adults Without Diabetes - March 2025](#)]


FinalFixRx Target Monthly Prescription Pricing: \$350
(plus \$10 monthly subscription fee for nurse support consultation)

Total Annual Patient Cost = \$4,320 (30% less than national average)

Year 3 SOM = **~\$778 million in annual revenue** (midpoint)
[~180K patients * \$4,320 annual price]



US Market



Product Design / Features

Smart, Integrated Support Through Mobile App

The FinalFixRx nebulizer device is designed to work seamlessly with its companion mobile app. Compact enough to fit in a small purse or pocket, the device enhances the patient experience while supporting optimized outcomes.

Track and log GLP/GIP dosage and usage patterns
Monitor key health metrics such as BMI, weight, and waist circumference

Provide reminders and adherence support

Generate reports for patient review or provider integration

Enable data sharing with physicians or wellness coaches

Offer **personalized insights and goal tracking**

This smart ecosystem empowers patients and providers with real-time insights, improves adherence, and creates a data-driven pathway to long-term health transformation.



Product Roadmap (with key milestones)

Phase 1

Proof of Concept via 503A Compounding

Product prepared and dispensed through 503A compounding pharmacies on a **patient-specific prescription** basis. Initial pilot study with **20 patients conducted under physician supervision**.

Duration: 1-month **testing period, completing by end of September 2025**.

Focus: Evaluate **safety, tolerability, and efficacy of GLP/GIP** nebulizer delivery.

Provides early access to targeted patients while ensuring full compliance with **503A regulatory standards**, with strict adherence to data privacy, quality, and patient protection—supported by the **highest standards of delivery** and customer care to foster safety, consistency, and patient confidence.

Phase 2

Integrated Telemedicine + Pharmacy (503A)

Model: Full in-house telemedicine platform integrated with pharmacy operations.

Scope: End-to-end patient experience, from **virtual consult to fulfillment**, ensuring seamless continuity of care.

Pharmacy Role: 503A compounding pharmacy prepares **patient-specific prescriptions**, including sterile/non-sterile compounds, peptides, hormones, dermatology, weight management, and wellness therapies.

Differentiator: Unlike competitors, all telehealth operations are fully **owned and operated** (not outsourced), giving complete control over patient experience, data, and compliance.

Patient Access: Online scheduling, virtual visits, streamlined prescribing, direct-to-door delivery.

Phase 3

Expanded Peptide & Wellness Platform


Model: National expansion of **telemedicine + 503A pharmacy**, with broader emphasis on **peptide therapies** and precision wellness solutions.

Scope: Compounding of a **full range of peptides** (including GLP/GIP), alongside hormone optimization, dermatology, weight management, longevity, and performance medicine.

Differentiator: Platform positions the business as a **leader in personalized peptide and wellness care**, supported by direct provider-pharmacy integration.

Growth: Multi-state reach, enhanced provider network, increased patient volume, and branding as a **go-to destination for peptides and advanced compounding**.

concept → prod dev → trial → marketing → presale → full launch → NDA



Capital Needs & Allocations

50%
\$2.5M

MARKETING & SALES

- Partner with marketing agency
- Target key segments & markets
- Engage in marketing events
- Regional & National Advertising

20%
\$1M

PRODUCT DEVELOPMENT

- Capabilities and enhancements
- Integrations to full mobile app features

20%
\$1M

OPERATIONS

- Licenses and platform fees
- Current team & org buildout

10%
\$0.5M

CONTINGENCY

**Target
Raise:
\$5M**

- Pre-money valuation target: ~\$20M
- Founder seeking strategic investor to help form the foundation for scale and growth

Let's Talk to Create Value at Scale

SimpleFix is partnering with the following consulting firm for its capital raising effort.



Invest with Us Today!

Investor Site

www.simplefixrx-investors.com

Email Us

info@simplefixrx-investors.com

Call Us

[888-470-5304](tel:888-470-5304)

All investor communications and document sharing will be managed by [Zarrugh Consultancy LLC](#)